Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nathan Itoga

Vascular Surgery Honolulu, HI Medical Doctor

NPI 1366880098 CMS profile 885950

1508 Laukahi St, Honolulu, HI 96821

Open in the dashboard

General payments

$20,762

161 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nathan Itoga of Honolulu, HI is reported in the CMS Open Payments database as having received $20,762 across 161 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,224 23
2024 General $8,504 36
2023 General $1,916 21
2022 General $2,047 29
2021 General $1,803 22
2020 General $796 13
2019 General $1,471 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nathan Itoga
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Nathan Itoga were reported at $4,224. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Nathan Itoga Vascular Surgery median Middle half National median
2019 $1,471 $796 $226–$2,363 $163
2020 $796 $348 $118–$1,110 $114
2021 $1,803 $471 $158–$1,421 $132
2022 $2,047 $725 $222–$2,183 $149
2023 $1,916 $836 $257–$2,440 $160
2024 $8,504 $909 $252–$2,619 $164
2025 $4,224 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $9,782 45 payments
  2. Silk Road Medical, Inc. $1,855 15 payments
  3. Abbott Laboratories $1,819 17 payments
  4. Shockwave Medical, Inc $1,527 12 payments
  5. Medtronic Vascular, Inc. $1,296 16 payments
  6. W. L. Gore & Associates, Inc. $1,266 11 payments
  7. Medtronic, Inc. $832 10 payments
  8. Bard Peripheral Vascular, Inc. $564 10 payments
  9. Bolton Medical Inc $434 3 payments
  10. Janssen Pharmaceuticals, Inc $241 8 payments
  11. Other $1,146 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,496 152 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,000 3 payments
  3. Travel and Lodging $1,004 4 payments
  4. Education $262 2 payments
Products named General payments · program years 2019–2025
  1. Indigo System $9,310 35 payments
  2. ENROUTE Transcarotid Stent $1,855 15 payments
  3. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,855 15 payments
  4. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $968 7 payments
  5. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $968 7 payments
  6. Endurant $949 13 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $845 3 payments
  8. XARELTO $388 9 payments
  9. IN.PACT AV $387 3 payments
  10. EXCLUDER Conformable AAA Endoprosthesis with Active Control $357 3 payments
  11. Other $6,025 74 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

185

Median for Vascular Surgery: 122

Drug cost

$65,259

Median for Vascular Surgery: $14,135

Branded share of claims

64.9%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 35 $36,612
Eliquis Apixaban Brand 19 $27,471
Clopidogrel Clopidogrel Bisulfate Brand 28 $443
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 38 $273
Doxycycline Hyclate Generic 19 $185
Gabapentin Generic 11 $109
Oxycodone Hcl Generic 19 $86
Tramadol Hcl Generic 16 $80

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$99,123

Medicare's payments for the services billed

Medicare patients

271

Average age 76

Services billed

929

113 women, 158 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 65%
Diabetes 64%
Ischemic heart disease 58%
Arthritis 40%
Heart failure 33%
Atrial fibrillation 30%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

161 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record